Analyst Coverage

Oryzon Genomics, S.A. is followed by the analysts listed below. Please note that any opinions, estimates or forecasts regarding Oryzon Genomics, S.A.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Oryzon Genomics, S.A. or its management. Oryzon Genomics, S.A. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.

 

Firm Analyst Report
ROTH Capital Partners (US) Jotin Marango

2018.04.30 - Oryzon Genomics - Initiation of Coverage

InResearch (ES) Luis Navia

2018.03 - Oryzon Genomics - Resultados 2017 (Spanish)

2017.11 - Oryzon Genomics - Resultados del 9M-2017 (Spanish)

2017.09 - Oryzon Genomics - Resultados del 1S-2017 (Spanish)

2017.05 - Oryzon Genomics - Resultados del 1T-2017 (Spanish)

2017.03 - Oryzon Genomics - Resultados 2016 y Actualización de Valoración (Spanish)

2016.11 - Oryzon Genomics - Resultados del 3T-2016 (Spanish)

2016.09 - Oryzon Genomics - Resultados del 1S-2016 (Spanish)

2016.05 - Oryzon Genomics - Resultados del 1T-2016 (Spanish)

2015.12 - Oryzon Genomics - A la Vanguardia de la Epigenética (Spanish)

Edison Group (UK) Jonas Peciulis

2018.05.22 - Oryzon Genomics - Phase IIa trial in Alzheimer’s disease initiated

2018.03.08 - Oryzon Genomics - Multiple data readouts in 2019 within cash reach

2017.12.14 - Oryzon Genomics - New data support holistic effects of ORY-2001

2017.08.22 - Oryzon Genomics - ORY-1001 rights back to Oryzon (Update Following Q2-2017 Results)

2017.05.22 - Oryzon Genomics - ORY-2001 and ORY-3001 next in focus (Update Following Q1-2017 Results)

2017.05.02 - Oryzon Genomics - Maturing epigenetics portfolio

2017.03.13 - Oryzon Genomics - New data further back MS indication (Update Following Q4-2016 Results)

2016.12.09 - Oryzon Genomics - Expanding clinical R&D pipeline

2016.11.16 - First look at ORY-1001 Phase I/IIa data

2016.11.03 - Fresh preclinical ORY-2001 data, ORY-1001 next (Update Following Q3-2016 Results)

2016.08.08 - Oryzon Genomics - Preliminary Phase I/IIa data read-out likely at ASH

2016.05.20 - Oryzon Genomics continues its march towards success

2016.03.16 - Oryzon Genomics - Initiation of coverage

Solventis (ES) Marta Traver
Manuel González

2018.05.21 - Research - Oryzon resultados Primer Trimestre 2018 (Spanish)

2017.11.23 - Oryzon avanza el Pipeline en fase clínica y aumentan las moléculas listas para iniciar Fase II (Spanish)

2017.01.09 - Oryzon avanza en sus estudios científicos y encuentra nuevos potenciales (Spanish)

2016.09.19 - Oryzon Genomics - Ciencia española “First in Class” a nivel mundial (Spanish)

BioNap, Inc. (US) Jason Napodano

2017.05 - Oryzon Genomics - Continued Progress, Promise with Oryzon's Pipeline (Update Following Q1-2017 Results))

2017.03 - Oryzon Genomics - Oryzon's Pipeline Taking Shape (Update Following Q4-2016 Results)

2016.12 - ORY-1001 Phase 1 Data At ASH In AL Looks Good For Oryzon, Roche

2016.10 - Oryzon Secures Financing, ORY-1001 Data Expected At ASH (Update Following Q3-2016 Results)

2016.08 - Oryzon Genomics - Oryzon Readies ORY-1001 Phase 2 Data For ASH, Advances ORY-2001 Into Phase 1b (Update Following Q2-2016 Results)

2016.05 - Oryzon Genomics - Advancing Epigenetic Based Therapeutics (Update Following Q1-2016 Results)

2015.12 - Oryzon Genomics - A Pioneer in The Field of Epigenetics